Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2016-12-07 Regulatory Filings
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details a corporate name change and amendments to the articles of incorporation and bylaws. It includes exhibits of the certificate of amendment and amended bylaws. There are no financial statements or detailed financial data presented. The document is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy statement or voting results announcement. The primary focus is on corporate governance changes related to the company's name and bylaws. Given the nature of the content and the form type (8-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-12-07 English
FORM 4
Director's Dealing
2016-12-02 English
FORM 4
Director's Dealing
2016-12-02 English
FORM 4
Director's Dealing
2016-12-02 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 30, 2016, for Oculus Innovative Sciences, Inc. The content focuses on announcements related to executive compensation, including bonuses awarded, new employment agreements, severance terms, and other management-related compensation details. There is no presentation of financial statements or comprehensive financial performance data. The document primarily announces changes and updates concerning senior management compensation and employment terms. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management, including compensation arrangements. The document is not an earnings release, annual report, or regulatory filing of another type, nor is it a proxy or remuneration report. Therefore, the appropriate classification is MANG with high confidence.
2016-12-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-11-30 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.